KIDS OrthoPediatrics Corp

OrthoPediatrics Corp. Launches DF2 Brace®

OrthoPediatrics Corp. Launches DF2 Brace®

WARSAW, Ind., Oct. 10, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today the limited release of the DF2® Brace as part of its expansion in the non-surgical business for treating kids with musculoskeletal injuries.

The DF2® Brace is intended for femur fracture fixation in pediatric patients from approximately 6 months to 5 years of age instead of spica cast by providing immobilization of the femur, knee, and hip.

Spica casts for femur fractures are considered the standard of care and have been used for decades, so the DF2® brace represents a significant advancement in how kids with femur fractures can be treated. This specific brace design has been studied in a multi-center trial and demonstrated equivalent outcomes both radiographically and clinically, and in most cases, eliminated the need to proceed to the operating room where the patient undergoes anesthesia.

Joe Hauser, President of Trauma and Deformity Correction at OrthoPediatrics, added, “This is the first product launch for the OrthoPediatrics Specialty Bracing group and will significantly improve the care of kids with femur fractures. The ability to eliminate anesthesia and complications associated with spica casts, all while reducing the overall cost of care is a significant advancement in pediatric orthopedics for patients, their families and surgeons.”

About OrthoPediatrics Corp.

Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets 52 surgical systems that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and over 70 countries outside the United States. For more information, please visit

Investor Contact

Philip Trip Taylor

Gilmartin Group



415-937-5406



EN
10/10/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OrthoPediatrics Corp

 PRESS RELEASE

OrthoPediatrics Corp. Continued Leading Sponsorship at 2025 POSNA Annu...

OrthoPediatrics Corp. Continued Leading Sponsorship at 2025 POSNA Annual Meeting Reinforced Long-Term Commitment as Emerald Sponsor WARSAW, Ind., May 14, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its continued support of the 2025 Pediatric Orthopaedic Society of North America (“POSNA”) annual meeting as an Emerald Sponsor. At the Annual Meeting, the Company will highlight its growing portfolio of pediatric-specific solutions, including...

 PRESS RELEASE

OrthoPediatrics Corp. Reports First Quarter 2025 Financial Results and...

OrthoPediatrics Corp. Reports First Quarter 2025 Financial Results and Increases Full Year 2025 Revenue Guidance First Quarter 2025 Revenue Increased 17% Year-over-Year WARSAW, Ind., May 07, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the first quarter ended March 31, 2025. First Quarter 2025 and Business Highlights Helped a record of nearly 39,000 children in the first quarter of 2025Generated total revenue of...

 PRESS RELEASE

OrthoPediatrics Corp. Expands Trauma and Deformity Portfolio with 3P™ ...

OrthoPediatrics Corp. Expands Trauma and Deformity Portfolio with 3P™ Pediatric Plating Platform™ Hip System WARSAW, Ind., May 07, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the expansion of its Trauma and Deformity portfolio with 3P™ Pediatric Plating Platform™ Hip System, the first of several systems in the 3P family. This represents the company’s 5th FDA approval in 2025. 3P Pediatric Plating Platform Hip System is a new plate and scre...

 PRESS RELEASE

OrthoPediatrics Corp. to Report First Quarter Financial Results on May...

OrthoPediatrics Corp. to Report First Quarter Financial Results on May 7, 2025 WARSAW, Ind., April 23, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its first quarter 2025 financial results on May 7, 2025 after the market closes. OrthoPediatrics will host a conference call on Wednesday, May 7, 2025 at 4:30 p.m. ET to discuss the results. Investors interested in listening to the conference call may do so...

 PRESS RELEASE

OrthoPediatrics Corp. Expands Scoliosis Portfolio with Launch of Verte...

OrthoPediatrics Corp. Expands Scoliosis Portfolio with Launch of VerteGlide™ System WARSAW, Ind., April 08, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the U.S. launch of the new VerteGlide Spinal Growth Guidance System, used to treat Early Onset Scoliosis (“EOS”). This represents the company’s 80th system designed to treat musculoskeletal issues in children. VerteGlide is a guided growth technology designed for children with Early Onset S...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch